Key message:

Survival trends for men and women with oral cavity cancer have improved slightly in England and Wales in recent years. Patients diagnosed at an early stage have significantly better prognosis than patients diagnosed with late stage cancer.  Early detection remains important for further increases in survival.

Oral Cavity Cancer: recent survival trends

Introduction

Oral cavity cancer is one of the most common types of head and neck cancer. In 2011 in England and Wales over 2,000 people were diagnosed with oral cavity cancer, 60% of which were men. The main risk factors are smoking, excessive alcohol consumption and the chewing of tobacco or paan (areca nut/betel leaf).

This briefing looks at recent trends in 1 and 3 year relative survivali in England and Wales. It highlights the effect of stageii at which the disease is detected as this is a key factor in survival.

Recent trends in relative survival

In general survival for women is better than for men. The 1 year relative survival for patients diagnosed between 2004 and 2011 with oral cavity cancer in England and Wales remains stable at 80% for men and 81% for women in 2011 (figure 1). The 3 year relative survival has significantly improved for men, rising from 58% in 2004/06 to 66% in 2008/10. Over the same time 3 year relative survival also increased for women, from 64% in 2004/06 to 68% in 2008/10, although the increase in women was not statistically significant.

Oral cavity figure 1

Figure 1: three year rolling trends in 1 and 3 year relative survival for men and women in England and Wales diagnosed with oral cavity cancer between 2004 and 2011 from DAHNO (Data for Head and Neck Oncology).

Survival and stage of diagnosis

The stage at which cancer is first detected predicts prognosis with patients presenting at an earlier stage of the disease having better survival than those at a late stage. In DAHNO (data audit for head and neck oncology) the recording of stage is good (78% in the latest year) so this has been used to analyse survival by stage. Figure 2a shows survival at 1 year is over 90% if diagnosed early. Relative survival at 1 year for late stage cancer is significantly worse. The gap has widened after 3 years: over 80% of patients diagnosed with early stage are still alive compared to under half those initiallydiagnosed at a later stage (see Figure 2b).

(a) 1 year relative survival by stage. 

Oral cavity figure 2

(b) 3 year relative survival by stage.

Oral cavity figure 3

Figure 2: relative survival for men and women by stage at 1 and 3 years between 2004 an 2011

Since 2004 the proportion of people diagnosed with early stage cancer has remained relatively consistent at around 40% of all cases. Despite accounting for 60% of total cases of oral cavity cancer men make up only 56% of early stage diagnoses.

Recommendations

  • Increasing awareness amongst the public of the main lifestyle risk factors for oral cancer could lead to a reduction in the number of cases of cancer
  • Increasing awareness about the early signs and symptoms of oral cancer could reduce the proportion of patients presenting at a late stage. See NHS Choices for symptoms check
  • Effective ways of targeting groups at risk of late presentation should be considered

Further information

This briefing was produced by the South East KIT in conjunction with the NCIN Head and Neck Cancer Site Specific Clinical Reference Group. For more information about oral cavity cancer and other types of head and neck cancer see the Head and Neck Cancer Hub on the NCIN website www.ncin.org.uk

i Relative survival is the ratio of the observed cumulative probability of survival in the cancer patients and the survival that would have been expected if the group had the background mortality in the general population (from England and Wales 2009 life tables).ii Stage is based on the size of the tumour(T), the extent of lymph node involvement (N) and the degree of metastatic spread (M). Early is defined as TNM stages 1 to 2 and late stage is 3 to 4.

FIND OUT MORE

South East Knowledge and Information Team (SEKIT) is the lead Cancer Registry for Head and Neck Cancer.

The National Cancer Intelligence Network (NCIN) is a UK-wide partnership operated by Public Health England. The NCIN coordinates and develops analysis and intelligence to drive improvements in prevention, standards of cancer care and clinical outcomes for cancer patients.